List of Latisse drug patents
Latisse is owned by Allergan.
Latisse contains Bimatoprost.
Latisse has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Latisse are:
- US9226931
- US8263054
- US9216183
- US8758733
- US8986715
- US8632760
Latisse was authorised for market use on 24 December, 2008.
Latisse is available in solution/drops;topical dosage forms.
Latisse can be used as method of stimulating hair growth; method of increasing hair growth, method of increasing hair growth, method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin, treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness, method of increasing growth of hair including eyelashes, method of increasing eyelash growth.
The generics of Latisse are possible to be released after 25 May, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8038988 | ALLERGAN | Method of enhancing hair growth |
Aug, 2023
(5 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9226931 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(2 months ago) | |
| US8263054 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(2 months ago) | |
| US9216183 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(2 months ago) | |
| US8758733 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(2 months ago) | |
| US8986715 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(2 months ago) | |
| US8632760 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(2 months ago) | |
| US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(1 year, 2 months from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of increasing eyelash growth; Method of increasing hair growth; Method of stimulating hair growth; Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness
Dosage: SOLUTION/DROPS;TOPICAL
LATISSE family patents
27
United States
5
Australia
3
European Union
1
Hong Kong
1
Canada
1
South Africa
1
Spain
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic